Drug intelligence / Profile preview

CR13626

Development stage: Preclinical
Lead developer: Rotta Research
Modality: Small Molecules
Administration: Oral

Overview

CR13626 is a preclinical-stage drug candidate being developed by Rottapharm Biotech (formerly part of Madaus/Rottapharm) for the treatment of glioblastoma. As of current pipeline disclosures, the specific molecular target and modality of CR13626 have not been publicly identified, although the "CR" prefix is traditionally used by the company to designate small molecule chemical entities. The program is part of Rottapharm's oncology portfolio and is currently undergoing preclinical studies to evaluate its potential in treating aggressive brain tumors.

Targets

MAP4K4 (Mitogen-activated protein kinase kinase kinase kinase 4)YES1 (YES proto-oncogene 1 tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)FYN (Proto-oncogene tyrosine-protein kinase Fyn)CDK6 (Cyclin-dependent kinase 6)EGFR T790M (Epidermal growth factor receptor T790M mutant)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)LCK (Proto-oncogene tyrosine-protein kinase Lck)

Beyond the preview

Go deeper on CR13626.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR13626.

Explore the full profile